anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a medicine preparation for preventing and treating ovarian cancer and a preparation method thereof. The medicine preparation is prepared from radix rubiae, herba portulacae, radix semiaquilegiae, cicada slough, centipedes, scorpion, earthworms, fructus leonuri, centella asiatica, hypericum perforatum, solidago virgaurea, herba eupatorii, sedum sarmentosum, eclipta, gentiana macrophylla, curcuma zedoary, burdock and licorice root. The medicine preparation has a good curative effect on ovarian cancer, has few side effects, can be applied for a long time, is hardly relapsed, does not have toxic or side effect, and does not generate drug resistance. The medicine preparation has an effective rate of over 90 percent after being taken for half a year. The invention aims to solve the technical problem of providing a traditional Chinese medicine prescription which is better in curative effect and fewer side effects in comparison with those of existing medicines and can be applied to control of ovarian cancer patient situations for a long time. The medicine preparation is prepared by using traditional Chinese medicinal materials as raw materials by means of a scientific formula through repeated verification of clinical tests, and accords with the theory of traditional Chinese medicine.
The experimental group will participate in 8 weeks of heart rate variability biofeedback practice using the Lief heart rate variability biofeedback Smart Patch and smartphone app + treatment as usual. Participants will be asked to, 1) wear the Lief Smart Patch for at least 8 hours per day, 2) do 15mins of scheduled heart rate variability biofeedback practice daily, and 3) use it as needed in response to negative affect in-the-moment.
NEW MATERIAL:Antitumor substances FNF I, II OR III (their physicochemical and biochemical properties are given in table I ; molecular weight 10,000; glycoprotein). USE:Antitumor substance. PREPARATION:Human fibroblasts are transformed into tumor cells (such as SV40 transformed cell) and the cells are made in a confluent state. The supernatant of the cell culture mixture is combined with cold saturated ammonium sulfate solution and, after left standing subjected to centrifugation under cooling. The precipitate is dissolved in a phosphate buffer. NaCl solution and subjected to column chromatography with Sephadex G100 to effect elution and fractionation with PBS. Each fraction is evaluated on the inclusion active of [<3>H] thymidine into 3T3 fibroblasts. Active fractions are collected, freeze-dried to collect the antitumor substance. The substance has been named FNF (fibroblast- originating necrotic factor) and acts only on tumor cells to inhibit them.
Elbow fractures are a challenging clinical problem. The advancement of science and technology has made major contributions to improve outcomes. Nonetheless, even with an anatomical restoration of the bone architecture, many patients stay with major limitations and pain. In clinical practice, it is striking to see how two patients with a similar elbow injury can exhibit completely opposite presentations: one who has completely healed from his/her injury and the other who has a stiff and painful elbow. The reasons for these changeable outcomes are unclear.

The investigator hypothesize that many of the answers will be related to the neurological system. This would explain why most studies strictly focusing on the orthopedic component of upper limb injury have yielded little improvement in preventing the adverse outcomes experienced by patients.

Following surgical treatment of an elbow fracture, patients often present with complications. Indeed, one third of patients complain of ulnar nerve symptoms after distal humerus fracture fixation, and 50% of patients treated surgically for elbow fracture-dislocations will have disabling stiffness and heterotopic ossification (HO). HO results from resident cells of mesenchymal origin in soft tissues transforming into bone. Furthermore, approximately half of all patients with fractures feel significant pain leading to persistent narcotic intake 3 months post injury; 40% will suffer from a neuropathic type of pain, which is poorly controlled by narcotic medication. Opioid usage is also related to increased sensitivity to pain (hyperalgesia) and dissatisfaction. Complications from opioids prolonged usage are numerous, from constipation to death due to an overdose. Canada is second worldwide, behind the United States, when it comes to opioid use and mortality secondary to opioid use. The majority of opioid dependant users were first exposed to these substances through medical prescriptions. This makes it imperative to improve the scinetific community understanding of pain mechanisms and find alternative treatments to opiates in the management of these injuries.

In view of these observations, the investigator's research must focus on something other than "satisfactory radiological results" in patients with elbow injuries. To this end, a multidisciplinary approach is needed. The investigators oversee research in elbow trauma, neurotrauma and have an expertise in upper limb evaluation. To improve the understanding of the underlying physiological principles that contribute to pain and chronic stiffness, one of the topics targeted by the investigator is the role of neuro-inflammation (NI) in chronic pain and functional limitation in elbow trauma. The surgical factors that increase NI will allow surgeons to choose different therapeutic options and develop novel treatments.
BACKGROUND: This prospective study was undertaken to report outcomes following reconstructive surgery for patients with painful pediatric idiopathic flexible flatfoot.
METHODS: Twenty-five patients with pediatric idiopathic flexible flatfoot were evaluated pre- and post flatfoot reconstruction with lateral column lengthening (LCL). All patients had lengthening of the Achilles or gastrocnemius, while 13 patients had medial side soft tissue (MSST) procedures, 7 underwent medial cuneiform plantarflexion osteotomy (MCPO), and 5 had medializing calcaneal osteotomy. Measures of static foot alignment-both radiographic parameters and clinical arch height indices-were compared, as were measures of dynamic foot alignment and loading, including arch height flexibility and pedobarography. Preoperative and postoperative patient-reported outcome (PRO) scores were compared between those treated with or without MSST procedures.
RESULTS: The median subject age was 13.8 years (range: 10.3 to 16.5) at the time of surgery. All radiographic parameters improved with surgery ( P <0.001). The mean sitting arch height index showed a modest increase after surgery ( P =0.023). Arch height flexibility was similar after surgery. The mean center-of-pressure excursion index increased from 14.1% to 24.0% ( P <0.001), and the mean first metatarsal head (MH) peak pressure dropped ( P <0.001), while the mean fifth MH peak pressure increased ( P =0.018). The ratio of peak pressure in the fifth MH to peak pressure in the second MH increased ( P =0.010). The ratio of peak pressure in the first MH to peak pressure in the second MH decreased when an MCPO was not used ( P <0.002), but it remained stable when an MCPO was included. Mean scores in all PRO domains improved ( P <0.001). Patients treated without MSST procedures showed no difference in PROMIS Pain Interference scores compared to those without MSST procedures.
CONCLUSIONS: Flatfoot reconstruction surgery using an LCL with plantarflexor lengthening results in improved PROs. LCL changes but does not normalize the distribution of MH pressure loading. The addition of an MCPO can prevent a significant reduction in load-sharing by the first MH.
Patients in this arm will take Sorafenib orally with the dose of 400mg bid on the third day after randomization till recurrence or the end of this trial. If any drug related adverse event occurred, the dosage will be reduced.
PROBLEM TO BE SOLVED: To obtain a humectant having excellent water retaining function and high safety, and capable of applying to a cosmetic, a bating agent, etc., by compounding SOUJYUTU(Atractylodis lanceae Rhizoma), that is, a kind of crude drug mainly prescribed as a Chinese medicine. SOLUTION: This humectant is produced by compounding SOUJYUTU, which is a dried extract obtained by extracting a rhizome of Atractylodes lancea with 30vol.% ethanol, or powdered SOUJYUTU obtained by pulverizing SOUJYUTU, as an active component. The humectant can be applied to an emulsion-type cosmetic such as a skin cream or a milky lotion, a skin external agent, a bathing agent, etc., by an ordinary formulation means. When used to a cream or a milky lotion, the humectant is added in about 0.01-10wt.%. In the case of a skin lotion, it may be compounded in an amount of about 0.01-15wt.%. Further, in the case of a bathing agent, the humectant is added in an amount of about 0.01-5wt.%.
A process for producing an arginine-rich peptide mixture and the application thereof in cervical cancer therapy is provided. The process includes the following steps: A suspension of walnut meal and egg albumin is pretreated with ultrahigh pressure, and then digested by alkaline proteinase and papain in separated steps with the ultrasonic and microwave-assisted extraction. The peptides of interest are isolated from filtration supernatant obtained after the enzyme digestion by reversed phase high-performance liquid chromatography. By using the peptide mixture as a template, acrylic acid and methyl acrylic acid as functional monomers, triethylene glycol dimethacrylate as cross-linking agent, and isopropylthioxanthone in acetone as a photoinitiator, polymerization is induced by ultraviolet light to form a surface imprinted membrane for isolating and enriching the peptides of interest from the supernatant. The arginine content in the peptide mixture is more than 18%. The arginine-rich peptide mixture is able to strongly suppress the proliferation of human cervical cancer Hela cells. The approach is applicable to reduce the cost of production and speed up the commercialization of large-scale production.
Apply daily at bedtime, in place of your regular toothpaste or more often if your dentist recommends additional therapy based on your diagnosis. Cover brush head with Pro-DenRx 1.1% Neutral Sodium Fluoride Gel and brush around all tooth surfaces and gum line for at least two minutes. Spit out gel. Adults: Wait 30 minutes before rinsing mouth. Children under 12: Rinse mouth thoroughly immediately after use. 

When using a mouthpiece or applicator, cover the inner surface with gel. Place applicator in mouth and bite down lightly for at least one minute. Remove applicator and rinse mouth. Clean applicator with cold water.
PURPOSE: This study aimed to investigate how intrinsic capacity (IC) deficit is associated with oral functional decline.
METHODS: This cross-sectional study enrolled older adults at a research hospital frailty clinic between July 2021 and May 2023. IC evaluation included the locomotion, cognition, vitality, psychology, and sensory domains. Criteria for deficits were established within each domain, and the number of IC deficit domains was calculated for each patient. Oral function assessment included oral hygiene, oral dryness, occlusal force, tongue-lip motor function, tongue pressure, masticatory function, and swallowing function. Patients who met three or more criteria were classified into the oral hypofunction (OHF) group. Univariate and multivariate logistic regression analyses were performed to investigate the relationship between IC deficit and OHF.
RESULTS: Of 222 included patients (mean age 78.3 ± 6.3 years; 39.6% men), 105 (47.3%) met the criteria for OHF. This OHF group showed a significantly higher prevalence of locomotion, cognition, psychology, and sensory domain deficits than the normal oral function group. Multivariate analysis adjusted for age and sex revealed a significant association between IC deficits and OHF (odds ratio [OR], 1.33; 95% confidence interval [CI] 1.04-1.70). A significant association was also observed between the locomotion domain and OHF (OR, 2.06; 95% CI 1.13-3.76).
CONCLUSION: This study highlights the potential relationship between the number of IC domain deficits and oral functional decline, with the most significant domain being locomotion. Furthermore, it suggests a possible link between sensory and oral function.
Fish oil has many proposed health benefits such as lowering triglycerides, decreasing inflammation, and reducing risk factors for cardiovascular disease. In order to take the recommended daily dose for hypertriglyceridemia using an OTC fish oil supplement, the daily recommended dose is at least 2 grams (2 capsules) three times a day. The American Heart Association recommends 2-4 grams of omega-3 fatty acid a day to aid in triglyceride reduction. Fish oil is known to cause GI-related adverse effects. Although reported to help, freezing fish oil capsules is inconvenient requiring access to a freezer three times a day. Currently there is a lack of literature to specify the best administration technique or patient compliance data for OTC fish oil supplements. The purpose of this study is to determine an ideal method of taking fish oil. This study will include up to 60 patients that are between the ages of 18-65 years who would be considered generally healthy. Patients will be recruited via e-mails sent to faculty and students of the School of Pharmacy, via flyers in Walgreen's stores, and through word of mouth. The patients will be randomly assigned to one of four treatment groups. Each treatment group will be given 180 capsules and instructed to take two capsules three times a day for thirty days with either food, no food, milk, or frozen. At the end of thirty days, the patient will return the bottle with any remaining pills to the investigator and take a survey. The investigators will assess compliance via pill count.
First treatment phase: Chemoimmunotherapy A-FMC maximum 4 cycles. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c.
Each subject will be their own control. Each subject will perform three 6MWTs. Intra-subject reproducibility is being tested.
PURPOSE: An antioxidant and a pharmaceutical composition which contain an Allium tuberosum Rottler extract as an effective ingredient are provided. The extract exhibits antioxidative activity and oxidative stress scavenging activity while having no toxicity and adverse effects. Therefore, the extract can be used as an antioxidant or a pharmaceutical composition for prevention of diseases caused by oxidative stress. CONSTITUTION: The antioxidant and pharmaceutical composition contain: a crude extract of Allium tuberosum Rottler which is extracted in lower alcohol such as water, ethanol and methanol, or a mixed solvent thereof, and its solvent extract which is soluble in a nonpolar solvent or a polar solvent; and additionally carriers, excipients and diluents. The nonpolar solvent is selected from hexane, chloroform, dichloromethane or ethyl acetate, the polar solvent is selected from acetone, butanol, ethanol, methanol or water. The recommended dosage of the extract ranges from 0.1 to 100mg/kg/day. A health beverage contains 0.02 to 10g of the extract on the basis of 100ml of beverage.
The human vitreous gel undergoes progressive liquefaction with age. Concurrent with the process of vitreous liquefaction, there is a weakening of the adhesion at the vitreoretinal interface between the cortical vitreous gel and the inner limiting lamina. Posterior vitreous detachment (PVD) is a separation of the cortical vitreous get from the inner limiting lamina. PVD is usually a sudden event during which liquefied vitreous from the center of the vitreous body bursts through a hole in the posterior vitreous cortex and then dissects the residual cortex gel away from the inner limiting lamina. If there is residual vitreoretinal traction around the break, this process may induce a tear in the retina that can in turn result in rhegmatogenous retinal detachment, macular hole, or cystoid macular edema. The importance of the vitreous in the progression of diabetic retinopathy may also extend beyond tractional considerations. For example, it is believed that the vitreous serves as scaffolding for new vessel formation and may also contribute to molecular imbalances that lead to retinopathy progression. Therefore, total PVD, by releasing vitreoretinal traction as well as other potential mechanisms, may be beneficial in various vitreoretinal diseases such as neovascular AMD.

Vitreomacular adhesion (VMA) in exudative (wet) AMD may be associated with poor prognosis in patients with AMD. This trial is primarily aimed at showing that release of VMA can be induced by microplasmin, a proteolytic enzyme, in patients with wet AMD, and that microplasmin is safe in patients w/ neovascular (wet) AMD. Secondary endpoint will be assessment of improved AMD outcomes.
Patients with severe ventricular dysfunction and coronary artery disease have high morbidity and mortality but may benefit from revascularization. However, there is also significant peri-operative morbidity and mortality among these patients. This accounts for the variable approach to these patients in different cardiac centres. Clearly this patient group has the most to gain when coronary revascularization is beneficial, but also the most to lose when it is not helpful. There is a need for an approach that can better define patients with severe ventricular dysfunction due to ischemia, who will be more likely to benefit from revascularization. Positron emission tomography (PET) imaging with F-18-Fluorodeoxyglucose (FDG) has been used to evaluate patients with ventricular dysfunction, to detect ischemic but viable myocardium more likely to recover from revascularization. Recently retrospective studies have shown that FDG PET can identify patients at high risk for cardiac events if they do not undergo revascularization. However, these studies did not evaluate whether FDG PET actually directed therapy decisions and because of their study design, could not determine whether FDG PET altered patient outcome. Our recent studies have shown that FDG PET can have important impact on therapy decisions and that patients with ischemic but viable myocardium are at increased risk. However it remains unclear whether an approach which utilizes FDG PET to define ischemic but viable myocardium can have a beneficial effect on patient outcome. It is also important to consider the potential clinical impact of FDG PET balanced against its limited availability. In addition, despite the cost of the technology, preliminary data from our group and others suggest a potential cost savings. Accordingly, a prospective randomized study is needed to evaluate whether FDG PET directed therapy has a beneficial effect on patient outcome and is cost-effective.
The invention relates to a traditional Chinese medicine preparation for treating superficial phlebitis. The traditional Chinese medicine preparation for treating superficial phlebitis is prepared by using the following raw medicinal materials by weight: 12g of Radix codonopsis, 12g of largehead atractylodes rhizome, 12g of Sichuan lovage rhizome, 10g of danshen root, 12g of safflower, 10g of Rhizoma corydalis, 15g of Caulis spatholobi, 12g of prepared common monkshood branched, 10g of cassia twig, 15g of Radix geutianae, 12g of honeysuckle bud and flower, 12g of Chinese thorowax root, 12g of kudzuvine root and 10g of largetrifoliolious bugbane rhizome. For patients with red and swollen symptoms, 12g of amur cork-tree, 10g of dandelion and 10g of lightyellow sophora root are added for clearing heat and removing toxins; for patients with great pains, 6g of prepared frankincense and 6g of prepared myrrh are added for promoting blood circulation and alleviating pain. A preparation method comprises the steps of taking the raw medicinal materials, adding a proper amount of water, soaking for 60 minutes, decocting for 30 minutes by using slow fire and filtering out residues to obtain decoction. One dose is taken per day at twice respectively at morning and evening. The traditional Chinese medicine preparation is prepared by using purely traditional Chinese medicines, the medicine efficacy is direct and the toxic and side effects are small.
Epitranscriptomic modification of tRNA has recently gained traction in the field of cancer biology. The presence of such modifications on tRNA appears to allow for translational control of processes central to progression and malignant transformation. Methyltransferase Like 1 protein (METTL1), along with other epitranscriptomic writers (e.g. NSUN3, NAT10, ELP3, etc.), has recently been investigated in multiple cancer types. Here, we review the impact of such tRNA modifications in tumorigenesis and the progression of cancer toward drug resistance and metastasis. Regulation of central cellular processes relied upon by malignant cancer cells through modulation of the tRNA epitranscriptome represents an area with great potential to bring novel first-in-class therapies to the clinic.
Erythrocytosis or polycythemia is defined as an increase in red blood cell concentration above the age- and sex-specific normal levels. Unlike anemia, which is very common in patients with chronic kidney disease (CKD), erythrocytosis is less frequent but requires specific understanding by health care professionals in order to provide the best care. Erythrocytosis, especially when undiagnosed and untreated, can lead to serious thrombotic events and higher mortality. Classic causes of erythrocytosis associated with CKD include cystic kidney diseases, kidney or other erythropoietin-secreting neoplasms, high-altitude renal syndrome, overdosage of erythropoietin-stimulating agents, androgen therapy, heavy smoking, chronic lung disease, obstructive sleep apnea, IgA nephropathy, post-kidney transplant erythrocytosis, renal artery stenosis, and congenital etiologies. After ruling out the common acquired causes of erythrocytosis and/or in the presence of suggestive parameters, primary erythrocytosis or polycythemia vera (PV) should be considered, and patients should be screened for JAK2V617F somatic mutation. The newest entity inducing erythrocytosis is linked to the use of sodium/glucose cotransporter 2 (SGLT2) inhibitors that hypothetically activate hypoxia-inducible factor 2α (HIF-2α) and in some cases unmask PV. This Review focuses on the pathogenesis, renal manifestations and management of PV, the pathophysiology of erythrocytosis induced by SGLT2 inhibitors and the relevance of timely JAK2 mutation screening in these patients.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse reactions in patients with stage 3 or 4 CKD

Doxercalciferol capsules have been evaluated in two placebo-controlled, double-blind 24 week studies in patients with Stage 3 or 4 CKD. Patients were treated with doxercalciferol capsules (n=27) or placebo (n=28) [see Clinical Studies (14.1)]. Adverse reactions occurring in the doxercalciferol capsules group at a frequency of 5% or greater and more frequently than in the placebo group are presented in Table 1.

Adverse reactions in patients with CKD on dialysis

Doxercalciferol capsules have been evaluated in two placebo-controlled, double-blind studies in patients with CKD on hemodialysis. Patients were treated with doxercalciferol capsules (n=61) or placebo (n=61) [see Clinical Studies (14.2)]. After randomization to two groups, eligible patients underwent an 8-week washout period during which no vitamin D derivatives were administered to either group. Subsequently, all patients received doxercalciferol capsules in an open-label fashion for 16 weeks followed by a double-blind period of 8 weeks during which patients received either doxercalciferol capsules or placebo. Adverse reactions occurring in the doxercalciferol capsule groups at a frequency of 2% or greater, and more frequently than in the placebo group are presented in Table 2.